The Global Fund Will Roll Out The Twice-yearly Anti-hiv Jab With Or Without Pepfar
The Global Fund for HIV, TB and Malaria says it will fund the roll-out of the twice-yearly anti-HIV jab, lenacapavir , for poorer countries, including South Africa, with or without the help of the US governments Aids fund, Pepfar.
Studies have shown lenacapavir is 100 effective for young women and 96 for gay and bisexual men .
In December, Pepfar and the Global Fund announced a commitment to fund the roll-out of lenacapavir in countries they support , once the medicine is registered with regulators.
But some fear that the Trump administrations recent termination of USAID-funded Pepfar projects is a sign that Pepfar will likely pull out of the deal.
That would be unwise, some experts say, especially if the Global Funds investment case is anything to go by.
In todays newsletter , Mia Malan explains how the twice-yearly HIV prevention jab, lenacapavir, will be rolled out with or without the US. Sign up for our newsletter today.
The Global Fund for HIV, TB and Malaria says it will fund the roll-out of the twice-yearly anti-HIV jab, lenacapavir , for poorer countries, including South Africa, with or without the help of the United States US governments Aids fund, Pepfar.
Pepfar is short for the US Presidents Emergency Plan for Aids Relief, the fund that US President Donald Trump has halted almost all support for over the past few weeks.
We are still maintaining our ambition on lenacapavir for PrEP, Global Fund executive director, Peter Sands, told Bhekisisa . We see lenacapavir as a potential game changer in the fight against HIV as an injectable, long acting PrEP solution that is pretty well 100 effective. Its not going to be right for everybody, but we need to find out more from having people use it.
PrEP, which is short for pre-exposure prophylaxis , is medicine that HIV-negative people can take to prevent themselves from contracting HIV through sex.